HYDERGINE LC
LOE ApproachingNDAORALCAPSULE
Approved
Jan 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE LC is an oral capsule small-molecule NDA approved in 1983 by Novartis. The generic name and mechanism of action are not specified in available data. Patient indications and clinical use case require further research.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team likely focused on lifecycle management and erosion mitigation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYDERGINE LC is a legacy product with zero linked job openings and approaching loss of exclusivity, indicating minimal career growth opportunity. Working on this product would focus on defensive strategies, generic preparation, and brand preservation rather than expansion.
Brand ManagerProduct Manager
Worked on HYDERGINE LC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.